Abstract: Objective To investigate the effectiveness of edaravone dexborneol on the outcome of acute cerebral infarction of different degrees.Methods A total of 180 patients with acute cerebral infarction who were admitted to the Affiliated Hospital of Xuzhou Medical University from January 2021 to December 2021 were selected. They were randomly divided into two groups (n=90): a control group and an observation group (edaravone dexborneol). Both groups were compared for serum inflammatory factors and neurological deficit scores before and after treatment. Acute cerebral infarction was subdivided into mild (NIHSS≤5 points) and medium-severe (NIHSS >5 points) subtypes, and then the clinical outcome was compared between the two treatment methods for patients with cerebral infarction of different degrees.Results There was no statistical difference in baseline data between the two groups before treatment (P>0.05). After treatment, inflammatory factors and NIHSS scores decreased in both groups (P<0.05). Compared with the control group, the observation group showed significant decreases in NIHSS scores and inflammatory factor levels (P<0.05). In the observation group, inflammatory factors and NIHSS in the medium-severe subgroup were lower than those in the light subgroup (P<0.05).Conclusions Edaravone dexborneol improves neurological deficits in acute cerebral infarction by reducing inflammatory factors, and is more effective in medium-severe acute cerebral infarction.